Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 19 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms CheckMate 817
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 19 Nov 2022 Pooled analysis from CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012) assessing OS, PFS, ORR, DOR, and safety published in the Annals of Oncology
    • 29 Aug 2022 Results of pooled analysis form CheckMate 227 Part 1, CheckMate 817 cohort A, CheckMate 568 Part 1 analyzing safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer, published in the Journal of Thoracic Oncology
    • 16 May 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top